drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Genetically engineered autologous T cells expressing chimeric antigen receptors targeting CD20 and/or CD30 on lymphoma cells to trigger MHC-independent T-cell activation and cytotoxic killing; given as a single IV infusion after lymphodepleting chemotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express chimeric antigen receptors that bind CD20 and/or CD30 on lymphoma cells, enabling MHC-independent recognition and activation via CD3ΞΆ/costimulatory signaling, leading to T-cell expansion, cytokine release, and cytotoxic killing of CD20+/CD30+ tumor cells after lymphodepleting chemotherapy.
drug_name
Autologous anti-CD20/CD30 CAR-T cells
nct_id_drug_ref
NCT06532643